Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

CAS No. :	38194-50-2
Formula :	C₂₀H₁₇FO₃S
M.W :	356.41
SMILES Code :	O=C(CC(C1=C2C=CC(F)=C1)=C(/C2=C/C3=CC=C(C=C3)S(C)=O)C)O
Synonyms :	MK-231
MDL No. :	MFCD00599589

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H317-H334-H361
Precautionary Statements:	P201-P202-P261-P264-P270-P272-P280-P284-P301+P310+P330-P302+P352-P304+P340-P308+P313-P333+P313-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

human colon cancer cell lines (HCCC)	70–79.3 µM	24 h	To study the effect of P-S on cell growth, P-S significantly inhibited cell proliferation and induced apoptosis.	Gastroenterology. 2010 Oct;139(4):1320-32.
NCM460 cells	100 µM	24 h	P-S showed lower toxicity to normal colon epithelial cells NCM460, indicating its selectivity for cancer cells.	Gastroenterology. 2010 Oct;139(4):1320-32.
GABAergic neurons	20 μM	2 days	Sulindac selectively induced apoptosis of GABAergic neurons, leading to hyperactive behavior in zebrafish larvae.	Nat Commun. 2023 Sep 2;14(1):5351.
PDO-AGR	5 nM	48 h	K-80003 enhanced the sensitivity to AG chemotherapy, significantly shrinking tumors and prolonging median survival.	Mol Cancer. 2024 Sep 30;23(1):215.
HCT116	100 μM	36 h	SS inhibits the growth of HCT116 cells and causes G1 phase cell cycle arrest.	Genes Dis. 2020 Nov 16;8(3):320-330.
HT29	100 μM	36 h	SS inhibits the growth of HT29 cells and causes G1 phase cell cycle arrest.	Genes Dis. 2020 Nov 16;8(3):320-330.
HEK 293T	5, 12.5, 25, 50, 75 µM	24 h	SS significantly inhibited Notch1 and APP C99 cleavage, but SF had a very modest effect.	Front Immunol. 2023 Oct 13;14:1244159.
H4	25, 50, 75, 100 µM	24 h	SS inhibited the cleavage of Notch1 and APP-C99 in a dose-dependent manner.	Front Immunol. 2023 Oct 13;14:1244159.
MDA-MB-231	10, 25, 50, 100 µM	48 h	SS inhibited the γ-secretase mediated release of the intracellular cytoplasmic domains of Notch1.	Front Immunol. 2023 Oct 13;14:1244159.
MDA-MB-231	5, 10, 25, 50, 100 µM	1 week	SS inhibited mammosphere growth in MDA-MB-231 cells in a dose-dependent manner.	Front Immunol. 2023 Oct 13;14:1244159.
C0321	5, 10, 25, 50, 100 µM	1 week	SS inhibited mammosphere growth in C0321 cells in a dose-dependent manner.	Front Immunol. 2023 Oct 13;14:1244159.
2K1 PDX	5, 10, 25, 50, 100 µM	1 week	SS dose-dependently decreased mammosphere growth in 2K1 PDX.	Front Immunol. 2023 Oct 13;14:1244159.

Mice	ZIKV-infected mouse model	Intraperitoneal injection	20 mg/kg	From 5 dpi till euthanasia or death	Sulindac, as an S100A4 inhibitor, was tested for its protective effects on ZIKV-induced testicular damage. The results showed that Sulindac was less effective than Niclosamide in inhibiting S100A4 expression.	Nat Commun. 2023 Apr 29;14(1):2476
Mice	Apcmin/+ mouse model	Oral gavage	30 mg/kg	Once daily for 3 weeks	To evaluate the effects of Sulindac alone and in combination with phosphatidylcholine (PC) on intestinal polyp burden in mice. Results showed that both Sulindac and Sulindac-PC significantly reduced polyp counts, and Sulindac-PC reduced gastric lesions.	BMC Cancer. 2020 Sep 10;20(1):871
Mice	Min mouse model	Intraperitoneal injection	1.875 mg/kg	Twice daily for 45 days	Sulindac was used as a positive control for tumour inhibition. In the single-agent study, Sulindac was less effective than MMPI or COX-2I, but still showed some tumour inhibition in the Min mouse model.	Br J Cancer. 2003 May 6;88(9):1445-52
Mice	Apc/Min mice	Oral	100 mg/kg/d	Once daily for 28 days	P-S significantly reduced the number of intestinal tumors in Apc/Min mice, demonstrating significant anticancer effects.	Gastroenterology. 2010 Oct;139(4):1320-32.
Mice	KM mice	Gastric feeding	26 mg/kg, 52 mg/kg, 104 mg/kg	Once daily for 30 days	Long-term administration of sulindac led to hyperactivity in mice and induced apoptosis of neocortical GABAergic neurons.	Nat Commun. 2023 Sep 2;14(1):5351.
Mice	PDOX model	Intraperitoneal injection	20 mg/kg	Twice weekly for 3 weeks	K-80003 significantly shrank tumors and prolonged median survival in vivo, with no significant drug toxicity observed.	Mol Cancer. 2024 Sep 30;23(1):215.
Mice	C0321 TNBC model	Oral	60 mg/kg	Daily for 14 days	SS significantly delayed tumor growth and reduced tumor mass without altering body mass.	Front Immunol. 2023 Oct 13;14:1244159.

{[proInfo.proName]}

CAS No.: 38194-50-2

{[proInfo.proName]}

CAS No.: 38194-50-2

Alternative Products

Product Details of Sulindac

Safety of Sulindac

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

NCT00275756	Glaucoma	Not Applicable	Withdrawn	-	Austria ... More >> Department of Clinical Pharmacology Vienna, Austria, A-1090 Less <<
NCT00283803	-		Completed	-	-
NCT02003703	Hepatitis B H... More >>IV Less <<	Phase 3	Recruiting	-	Chile ... More >> Hospital Gustavo Fricke Recruiting Viña del Mar, Valparaíso, Chile Contact: Jose I Vargas, MD 62473415 ext +56 9 jivargasd@icloud.com Contact: Daniela Jensen, MD 62473409 ext +56 9 daniela_jensen@hotmail.com Principal Investigator: Jose I Vargas, MD Principal Investigator: Daniela Jensen, MD Principal Investigator: Francisco Fuster, MD Principal Investigator: Valeska Sarmiento Less <<
NCT00041054	Lung Cancer	Phase 2	Completed	-	-
NCT00052845	Prostate Cancer	Phase 2	Completed	-	-
NCT00041314	Lung Cancer	Phase 2	Completed	-	-
NCT00140933	Pain	Phase 3	Terminated	-	France ... More >> Laboratoires Merck Sharp & Dohme - Chibret Paris Cedex 8, France, 75114 Less <<
NCT00037609	Breast Neoplasms ... More >> Metastases, Neoplasm Less <<	Phase 1 Phase 2	Completed	-	United States, Texas ... More >> University of Texas M. D. Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT00085826	Non-Small Cell Lung Cancer	Phase 3	Completed	-	-
NCT00166426	Prostatic Neoplasms	Phase 2	Completed	-	United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00166478	Prostatic Neoplasms	Phase 2	Completed	-	United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT00026468	Colorectal Cancer ... More >> Small Intestine Cancer Less <<	Phase 2 Phase 3	Withdrawn(Principle Investigat... More >>or has left the University.) Less <<	-	-
NCT00283803	Prostate Cancer	Phase 2	Completed	-	United States, Washington ... More >> Seattle Cancer Care Alliance Seattle, Washington, United States, 98109 Less <<
NCT00927485	Familial Adenomatous Polyposis	Not Applicable	Completed	-	Puerto Rico ... More >> University of Puerto Rico Comprehensive Cancer Center San Juan, Puerto Rico, 00936 Less <<
NCT00176618	Aberrant Crypt Foci	Not Applicable	Terminated(principal Investiga... More >>tor left institution) Less <<	-	United States, New Jersey ... More >> Cancer Institute of New Jersey New Brunswick, New Jersey, United States, 08901 Less <<
NCT00078910	Prostate Cancer	Phase 2	Completed	-	United States, Arizona ... More >> Mayo Clinic Scottsdale Scottsdale, Arizona, United States, 85259-5499 United States, Florida Mayo Clinic - Jacksonville Jacksonville, Florida, United States, 32224 United States, Minnesota Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 Less <<
NCT00003365	Colorectal Cancer	Not Applicable	Terminated(Study completed)	-	United States, New York ... More >> Rockefeller University Hospital New York, New York, United States, 10021-6399 Less <<
NCT00319007	Adenomatous Polyposis Coli	Phase 2	Unknown	-	Netherlands ... More >> Radboud University Nijmegen Medical Centre Recruiting Nijmegen, Netherlands, 6533DD Contact: Pieter Friederich, MD 00-31-24-3614760 P.Friederich@mdl.umcn.nl Contact: Fokko M Nagengast, PhD 00-31-24-3504066 F.Nagengast@mdl.umcn.nl Principal Investigator: Pieter P Friederich, MD Less <<
NCT00039520	Breast Cancer	Phase 2	Completed	-	United States, Pennsylvania ... More >> Fox Chase Cancer Center Philadelphia, Pennsylvania, United States, 19111 Less <<
NCT01187901	Adenomatous Polyposis Coli	Phase 2	Completed	-	United States, Utah ... More >> Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Less <<
NCT01187901	-		Completed	-	-
NCT00335504	Colon Cancer ... More >>Precancerous Condition Rectal Cancer Less <<	Phase 2	Completed	-	United States, Minnesota ... More >> Mayo Clinic Rochester, Minnesota, United States, 55905 Less <<
NCT01761877	Inflammation\|Cancer\|Pain\|Hyper... More >>tension Less <<	PHASE2	COMPLETED	2019-03-11	University of Arizona Cancer C... More >>enter, Tucson, Arizona, 85724, United States\|Stony Brook University Cancer Center, Stony Brook, New York, 11794, United States Less <<
NCT00343629	Unspecified Adult Solid Tumor,... More >> Protocol Specific Less <<	Not Applicable	Completed	-	United States, Minnesota ... More >> Mayo Clinic Cancer Center Rochester, Minnesota, United States, 55905 Less <<
NCT01515137	Head and Neck Squamous Cell Ca... More >>rcinoma Less <<	Phase 1	Completed	-	United States, Pennsylvania ... More >> University of Pittsburgh Cancer Institute Pittsburgh, Pennsylvania, United States, 15232 Less <<
NCT00062023	Colorectal Cancer	Phase 2	Terminated(Study closed by the... More >> NCI.) Less <<	-	United States, Texas ... More >> M.D. Anderson Cancer Center at University of Texas Houston, Texas, United States, 77030-4009 Less <<
NCT00068419	Desmoid Tumor	Phase 2	Active, not recruiting	-	United States, California ... More >> Children's Oncology Group Monrovia, California, United States, 91016 Less <<
NCT00068419	-		Active, not recruiting	-	-
NCT00755976	Melanoma (Skin)	Phase 2	Completed	-	Ireland ... More >> Cork University Hospital Cork, Ireland Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital Dublin, Ireland, 24 St. Vincent's University Hospital Dublin, Ireland, 4 Mater Misericordiae University Hospital Dublin, Ireland, 7 St. James's Hospital Dublin, Ireland, 8 Beaumont Hospital Dublin, Ireland, 9 National Institute for Cellular Biotechnology at Dublin City University Dublin, Ireland, 9 Galway University Hospital Galway, Ireland Mid-Western Cancer Centre at Mid-Western Regional Hospital Limerick, Ireland, 0009 Waterford Regional Hospital Waterford, Ireland Less <<
NCT00118365	Precancerous Condition	Phase 3	Completed	-	United States, California ... More >> University of California Medical Center At Irvine-Orange Campus Orange, California, United States, 92868 Less <<
NCT00245024	Breast Cancer	Phase 1	Completed	-	United States, Arizona ... More >> Arizona Cancer Center at University of Arizona Health Sciences Center Tucson, Arizona, United States, 85724-5024 Less <<
NCT00118365	-		Completed	-	-
NCT00368927	Precancerous Condition ... More >> Stage I Non-small Cell Lung Cancer Tobacco Use Disorder Less <<	Phase 2	Completed	-	United States, Arizona ... More >> Mayo Clinic in Arizona Scottsdale, Arizona, United States, 85259 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Tampa, Florida, United States, 33612 United States, Massachusetts Lahey Hospital and Medical Center Burlington, Massachusetts, United States, 01805 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Canada, British Columbia British Columbia Vancouver, British Columbia, Canada, V5Z 1L3 Less <<
NCT00392665	Squamous Cell Carcinoma of the... More >> Head and Neck (SCCHN) Less <<	Phase 2	Terminated(slow accrual)	-	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02115 Less <<
NCT00368927	-		Completed	-	-
NCT00072618	NSCLC	Phase 1 Phase 2	Completed	-	United States, Colorado ... More >> University of Colorado Health Sciences Center Aurora, Colorado, United States, 80045 United States, Illinois University of Chicago Medical Center Chicago, Illinois, United States, 60637 Less <<
NCT00392665	-		Terminated(slow accrual)	-	-
NCT01483144	Familial Adenomatous Polyposis	Phase 3	Active, not recruiting	June 2019	United States, California ... More >> University of California San Diego La Jolla, California, United States, 92093 United States, Georgia Emory University Atlanta, Georgia, United States, 30322 United States, Massachusetts Dana Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Michigan University of Michigan Ann Arbor, Michigan, United States, 48109 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Washington University Saint Louis, Missouri, United States, 63110 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Pennsylvania University of Pennsylvania Philadelphia, Pennsylvania, United States, 19104 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 United States, Utah University of Utah- Huntsman Cancer Institute Salt Lake City, Utah, United States, 84112 Belgium UZ Leuven Leuven, Belgium, 3000 Canada, Ontario Zane Cohen Centre For Digestive Diseases Toronto, Ontario, Canada, M5T 3L9 Germany University Hospital Bonn Bonn, Germany, 53105 Netherlands Academic Medical Centre Amsterdam, Netherlands, 1100 DE Spain Institut de Malalties Digestives Barcelona, Catalonia, Spain, 08036 United Kingdom Institute of Genetic Medicine Newcastle Upon Tyne, Tyne And Wear, United Kingdom, NEI 3BZ Manchester Center for Genomic Medicine Manchester, United Kingdom, M13 NWL Less <<
NCT00335504	-		Completed	-	-
NCT01349881	Colorectal Neoplasms	Phase 3	Recruiting	July 2029	-
NCT01856322	Colorectal Cancer ... More >> Liver Metastasis Colorectal Adenocarcinoma Less <<	Phase 2	Terminated(The trial was prema... More >>turely closed due to lack of accrual.) Less <<	-	United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00841204	Precancerous Condition	Phase 2	Completed	-	United States, Arizona ... More >> University of Arizona Health Sciences Center Tucson, Arizona, United States, 85724 United States, California Stanford University Hospitals and Clinics Stanford, California, United States, 94305 Less <<
NCT01245816	Familial Adenomatous Polyposis	Phase 3	Withdrawn	June 2013	-
NCT01856322	-		Terminated(The trial was prema... More >>turely closed due to lack of accrual.) Less <<	-	-
NCT01636128	Focus of Study: Drug Response ... More >>Biomarkers, Chemoprevention, Neoplasms Less <<	Phase 2	Withdrawn(Funding and staffing... More >>) Less <<	April 2016	-
NCT00299195	Leukoplakia, Oral ... More >> Benign Neoplasms Less <<	Not Applicable	Active, not recruiting	June 2019	United States, New York ... More >> Memorial Sloan Kettering Cancer Center New York, New York, United States, 10065 India Amrita Institute of Sciences (AIMS) Cochin, India Regional Cancer Center (RCC) Trivandrum, India Less <<
NCT01843179	Acute Myeloid Leukemia	Phase 2	Withdrawn(Lack of Funding)	-	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02115 Less <<
NCT00841204	-		Completed	-	-

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	2.81mL 0.56mL 0.28mL	14.03mL 2.81mL 1.40mL	28.06mL 5.61mL 2.81mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed